Zacks Investment Research upgraded shares of Obalon Therapeutics (NASDAQ:OBLN) from a hold rating to a buy rating in a research note published on Tuesday, Zacks.com reports. The brokerage currently has $2.00 price target on the stock.
According to Zacks, “Obalon Therapeutics, Inc. is a medical device company. It focused on developing and commercializing medical devices to treat obese and overweight. The company’s product consists of Obalon balloon system, the first swallowable, gas-filled intragastric balloon designed to provide progressive and sustained weight loss in obese patients. Obalon Therapeutics, Inc. is based in San Diego, California. “
Shares of Obalon Therapeutics stock opened at $1.85 on Tuesday. Obalon Therapeutics has a 52-week low of $1.52 and a 52-week high of $23.30. The stock has a market capitalization of $14.30 million, a price-to-earnings ratio of -0.17 and a beta of -4.63. The company has a fifty day moving average of $1.85 and a 200-day moving average of $2.06. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.20 and a current ratio of 5.72.
About Obalon Therapeutics
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.
Recommended Story: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Obalon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.